Enorama Pharma AB (OSTO:ERMA) Forward Dividend Yield %: 0.00% (As of Jun. 30, 2026)


OSTO:ERMA Enorama Pharma AB OSTO:ERMA
28 GF Score
Price kr0.29
GF Value kr0.42
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Enorama Pharma AB Forward Dividend Yield %?

Enorama Pharma AB OSTO:ERMA +13.33% 28 Forward Dividend Yield % is 0.00% as of Jun. 30, 2026. GuruFocus rates OSTO:ERMA with a GF Score™ of 28/100 and a GF Value™ of kr0.42 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 505 Drug Manufacturers companies, Enorama Pharma AB ranks worse than 198019.6% on this metric.

As of today (2026-06-30), the Forward Annual Dividend Yield of Enorama Pharma AB is 0.00%.

As of today (2026-06-30), the Trailing Annual Dividend Yield of Enorama Pharma AB is 0.00%.

OSTO:ERMA's Forward Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.12
* Ranked among companies with meaningful Forward Dividend Yield % only.

Enorama Pharma AB's Dividends per Share for the three months ended in Mar. 2026 was kr0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Enorama Pharma AB  (OSTO:ERMA) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Enorama Pharma AB Forward Dividend Yield % Related Terms


OSTO:ERMA vs ZTS, UTHR, VTRS: Forward Dividend Yield % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Enorama Pharma AB's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enorama Pharma AB Forward Dividend Yield % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Enorama Pharma AB's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Enorama Pharma AB's Forward Dividend Yield % falls into.


OSTO:ERMA
28GF Score
Enorama Pharma AB OSTO:ERMA
Forward Dividend Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enorama Pharma AB Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

What does a Forward Dividend Yield % of 0.00% mean?
Enorama Pharma AB (OSTO:ERMA) has a Forward Dividend Yield % of 0.00% as of Jun. 30, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Enorama Pharma AB and its competitors. According to the industry distribution chart, Enorama Pharma AB ranks #999999 out of 505 companies in the Drug Manufacturers industry.
Is Enorama Pharma AB's Forward Dividend Yield % too high?
Enorama Pharma AB's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Enorama Pharma AB ranks #999999 out of 505 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Enorama Pharma AB has a GF Score™ of 28/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Enorama Pharma AB's Forward Dividend Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Enorama Pharma AB ranks #999999 out of 505 companies for Forward Dividend Yield %. This places Enorama Pharma AB in the lower half of its industry. The industry median Forward Dividend Yield % is 2.12. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 2.12, based on 505 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Enorama Pharma AB and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 2.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Enorama Pharma AB's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enorama Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, Enorama Pharma AB (OSTO:ERMA) is currently considered Possible Value Trap. The stock's GF Value™ is kr0.42, compared to a current price of kr0.29 — trading 31.2% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. Enorama Pharma AB's overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Enorama Pharma AB (OSTO:ERMA), the current Forward Dividend Yield % is 0.00% as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Enorama Pharma AB (OSTO:ERMA) Overvalued in 2026?

Based on GuruFocus' analysis, Enorama Pharma AB stock appears to be undervalued. The current stock price of kr0.29 is trading 31.2% below its estimated GF Value™ of kr0.42. GuruFocus considers Enorama Pharma AB to be Possible Value Trap.

Key valuation signals for OSTO:ERMA:

  • Forward Dividend Yield %: 0.00%
  • GF Value™: kr0.42 vs. price of kr0.29 (31.2% below fair value)
  • GF Score™: 28/100 with 4 warning signs

No single metric tells the full story. See the OSTO:ERMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Enorama Pharma AB Business Description

Address Vastra Varvsgatan 19, Malmo, SWE, SE-211 77
Enorama Pharma AB is a pharmaceutical company that focuses on consumer-friendly medicated chewing gum containing generic substances. It provides medicated gums containing generic pharmaceutical substances, developed through its ChewMed technology platform.
28GF Score

Get the complete analysis for OSTO:ERMA

Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.29
Price
kr0.42
GF Value